公开(公告)号：US20170196933A1

公开(公告)日：2017-07-13

申请号：US15313767

申请日：2015-05-27

Applicant: Stealth BioTherapeutics Corp

Inventor： D. Travis Wilson

IPC: A61K38/10 ,  A61K38/08 ,  A61K38/06 ,  A61K38/05 ,  A61K38/13 ,  A61K38/53 ,  A61K38/40 ,  A61K38/44 ,  A61K38/46 ,  A61K38/45 ,  A61K38/51 ,  A61K38/07 ,  A61K38/17

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH2.

公开(公告)号：US09687533B2

公开(公告)日：2017-06-27

申请号：US14577510

申请日：2014-12-19

Applicant: aTyr Pharma Inc. ,  Pangu Biopharma Limited

Inventor： Leslie Ann Greene ,  Kyle P. Chiang ,  Fei Hong ,  Alain P. Vasserot ,  Wing-Sze Lo ,  Jeffry D. Watkins ,  Cheryl L. Quinn ,  Zhiwen Xu ,  John D. Mendlein

IPC: C12N9/18 ,  A61K38/00 ,  A61K38/53 ,  C12N9/00 ,  G01N33/573

CPC classification number: A61K38/53 ,  A61K38/00 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/55 ,  C12N5/0602 ,  C12N9/93 ,  C12N9/96 ,  C12Y601/0102 ,  G01N33/573 ,  G01N33/68 ,  G01N2333/9015 ,  G01N2500/00

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

公开(公告)号：US09629804B2

公开(公告)日：2017-04-25

申请号：US14521161

申请日：2014-10-22

Applicant: Shire Human Genetic Therapies, Inc. ,  Massachusetts Institute of Technology

Inventor： Michael Heartlein ,  Daniel Anderson ,  Yizhou Dong ,  Frank DeRosa

IPC: A61K31/497 ,  A61K9/127 ,  A61K38/17 ,  A61K38/48 ,  A61K38/53 ,  A61K48/00

CPC classification number: A61K9/1272 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/4846 ,  A61K38/53 ,  A61K48/00 ,  A61K48/0033 ,  A61K48/005

Abstract: The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.

公开(公告)号：US09623093B2

公开(公告)日：2017-04-18

申请号：US14620548

申请日：2015-02-12

Applicant: aTyr Pharma, Inc. ,  Pangu BioPharma Limited

Inventor： Leslie Ann Greene ,  Kyle P. Chiang ,  Fei Hong ,  Alain P. Vasserot ,  Wing-Sze Lo ,  Jeffry D. Watkins ,  Cheryl L. Quinn ,  John D. Mendlein

IPC: C07K14/47 ,  C07K14/35 ,  A61K38/53 ,  C12N9/10 ,  C12N9/00 ,  G01N33/50 ,  G01N33/68 ,  C12N9/96 ,  A61K35/12 ,  C07K14/00 ,  G01N33/573 ,  A61K38/00

CPC classification number: C07K16/40 ,  A61K35/12 ,  A61K38/00 ,  A61K38/53 ,  C07K14/00 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2319/33 ,  C12N9/1085 ,  C12N9/93 ,  C12N9/96 ,  C12Y601/01 ,  G01N33/5008 ,  G01N33/573 ,  G01N33/68 ,  G01N2333/9015 ,  G01N2500/00

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

公开(公告)号：US20170072031A1

公开(公告)日：2017-03-16

申请号：US15362196

申请日：2016-11-28

Applicant: Medicinal Bioconvergence Research Center

Inventor： Sunghoon Kim ,  Min Chul Park

IPC: A61K38/53 ,  A61K38/17 ,  C12N9/00

CPC classification number: A61K38/53 ,  A61K35/15 ,  A61K38/1709 ,  A61K38/1719 ,  A61K38/1774 ,  A61K38/179 ,  C12N9/00 ,  C12N9/93 ,  C12Y601/01004 ,  C12Y601/01005 ,  C12Y601/01014 ,  A61K2300/00

Abstract: The present invention relates to nanoparticles comprising aminoacyl tRNA synthetase and an anticancer composition comprising the same and, specifically, to nanoparticles which comprise glycyl-tRNA synthetase (GRS), leucyl-tRNA synthetase (LRS), and isoleucyl-tRNA synthetase (IRS), and have anticancer or immunostimulating activity; a pharmaceutical composition for preventing or treating cancer, comprising the nanoparticles as an active ingredient; a composition for immunostimulation; and a method for preparing the nanoparticles.

Abstract translation: 本发明涉及包含氨酰tRNA合成酶的纳米颗粒和包含其的抗癌组合物，特别涉及包含甘氨酰tRNA合成酶（GRS），亮氨酰-tRNA合成酶（LRS）和异亮氨酰-tRNA合成酶（IRS）的纳米颗粒， 并具有抗癌或免疫刺激活性; 用于预防或治疗癌症的药物组合物，其包含所述纳米颗粒作为活性成分; 用于免疫刺激的组合物; 和制备纳米颗粒的方法。

公开(公告)号：US20170045520A1

公开(公告)日：2017-02-16

申请号：US15305905

申请日：2015-04-24

Applicant: National University of Singapore

Inventor： Yoon Pin Lim

IPC: G01N33/574 ,  A61K38/53 ,  C12Q1/68

CPC classification number: G01N33/57496 ,  A61K38/53 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Y603/02019 ,  G01N33/57484 ,  G01N2333/9015 ,  G01N2800/52

Abstract: The present invention provides a method of predicting response of a cancer patient to a therapy. The method comprises the step of determining a presence or absence of at least one mutation of ITCH (SEQ ID NO: 1) in a first sample isolated from a cancer patient, wherein the presence of a mutation is predictive of response of the cancer patient to a therapy selected from the group consisting of: Wnt pathway-, EGFR-, Her2-, hormonal- and WBP2-based therapy.

Abstract translation: 本发明提供一种预测癌症患者对治疗的反应的方法。 该方法包括确定在从癌症患者分离的第一样品中存在或不存在ITCH（SEQ ID NO：1）的至少一个突变的步骤，其中突变的存在预示着癌症患者的反应 选自以下的治疗剂：Wnt途径，EGFR-，Her2-，基于激素和WBP2的治疗。

公开(公告)号：US09499810B2

公开(公告)日：2016-11-22

申请号：US14180126

申请日：2014-02-13

Applicant: aTyr Pharma, Inc.

Inventor： Rajesh Belani ,  Jeffry Dean Watkins ,  Wei Zhang ,  Alain Phillippe Vasserot

IPC: A61K38/54 ,  A61K38/00 ,  C07K1/00 ,  C12N9/00 ,  A61K38/53 ,  C12N9/96

CPC classification number: A61K38/53 ,  C12N9/93 ,  C12N9/96 ,  C12Y601/01001 ,  Y02A50/385

Abstract: Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia.

Abstract translation: 提供了包含酪氨酰tRNA合成酶多肽（包括其截短和/或变体）的造血组合物。 还提供了使用这些组合物治疗有益于增加血小板生成（例如血小板减少症）的病症的方法。

公开(公告)号：US20160312207A1

公开(公告)日：2016-10-27

申请号：US15134353

申请日：2016-04-20

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Calvin J. Kuo ,  Kelley Yan ,  Junlei Chang

IPC: C12N9/00 ,  A61K9/00 ,  A61K38/53 ,  C12N7/00

CPC classification number: C12N9/93 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/53 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2710/10343 ,  C12Y603/02

Abstract: Compositions and methods for treating cancer associated with aberrant activation of the Wnt signaling pathway are disclosed. In particular, the invention relates to R-spondin antagonists comprising a soluble extracellular domain of ring finger 43 (RNF43) or E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) and methods of treating cancer with such antagonists.

Abstract translation: 公开了治疗与Wnt信号通路异常激活相关的癌症的组合物和方法。 特别地，本发明涉及包含无名指43（RNF43）或E3泛素连接酶锌和无名指3（ZNRF3）的可溶性细胞外结构域的R-spondin拮抗剂以及用这种拮抗剂治疗癌症的方法。

公开(公告)号：US20160136123A1

公开(公告)日：2016-05-19

申请号：US14898062

申请日：2014-05-29

Applicant: Vojo P. DERETIC ,  Michale MANDELL ,  STC.UNM

Inventor： Vojo P. Deretic ,  Michael Mandell

IPC: A61K31/201 ,  C12Q1/61 ,  C12Q1/44 ,  A61K45/06 ,  A61K38/53

CPC classification number: A61K31/201 ,  A61K38/53 ,  A61K45/06 ,  C12N9/93 ,  C12Q1/44 ,  C12Q1/61 ,  C12Y603/02 ,  G01N2333/92 ,  G01N2405/00 ,  G01N2405/02 ,  G01N2500/20 ,  G01N2800/7028

Abstract: The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions.

Abstract translation: 本发明涉及使用中性脂质，包括甘油三酸酯，甘油二酯和甘油单酯，其可用于增加中性脂质（脂质储存和/或脂质液滴）和中性脂质储存物，以调节（特别是诱导）自噬和 治疗和/或预防自噬相关疾病状态和/或病症。 在一个实施方案中，本发明涉及可用于调节（特别是诱导）自噬，靶自噬底物并治疗和/或预防自噬性疾病状态和/或病症的中性脂质和/或TRIM蛋白的用途。

公开(公告)号：US20160122742A1

公开(公告)日：2016-05-05

申请号：US14894428

申请日：2014-06-02

Applicant: Marcel MECHALI ,  Coulombe PHILIPPE

Inventor： Marcel MECHALI ,  Philippe COULOMBE

IPC: C12N9/00 ,  A61K38/53 ,  C12N15/113

CPC classification number: C12N9/93 ,  A61K38/53 ,  C07K14/47 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/30 ,  C12Y603/02019

Abstract: A composition including at least a protein consisting of an amino acid sequence as set forth in SEQ ID NO: 1, or a salt or a solvate thereof, in association with a pharmaceutically acceptable carrier, for its use for treating pathologies link to DNA replication.

Abstract translation: 至少包含由SEQ ID NO：1所示的氨基酸序列组成的蛋白质或其药学上可接受的载体的盐或其溶剂合物的组合物，用于治疗与DNA复制有关的病理学的用途。